Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma

Abstract

This multimodal treatment is feasible, safe and tolerated reasonably well and would be suitable for use in multi-institutional prospective randomized clinical trials incorporating novel therapies in patients with UPSC.

Analysis of Treatment Failures and Survival of Patients With Uterine Papillary Serous Carcinoma: A Cooperation Task Force (CTF) Study

“…5Y10,16,19,20 In a retrospective study on 142 patients with stage I UPSC, 25 recurrences (17.6%) were diagnosed; 72% of these occurred within 2 years, and 60% were extrapelvic. 19 In the series of Obermair et al, 20 44.8% of the 29 patients with stage I to stage III disease had recurrence, and most relapses were distant (38.4%). In our investigation, tumor recurred in 37.0% of the patients after a median time of 15.1 months, and recurrent disease involved peritoneum or distant sites in 66.7% of the cases.…”

Outcomes and toxicities for the treatment of stage IVB cervical cancer

“…Although we cannot be certain, there is a possibility that concurrent radiotherapy with paclitaxel/ carboplatin chemotherapy in patients with stage IVB cervical cancer might be at least as effective as FP chemotherapy and less toxic when combined with radiotherapy than FP used based on the reported incidence of toxicities of combined paclitaxel/carboplatin and RT [11,12]. CP and 5-FU are radio-sensitizing agents, severe adverse reactions have been observed in many patients who received FP chemotherapy and radiation therapy [9,13], whereas the combination of carboplatin and paclitaxel showed activity with an acceptable toxicity profile in patients with advanced or recurrent cervical carcinoma [14,15], and thus might be more acceptable when used concurrently with radiation therapy.…”

Adjuvant Therapy in Early-Stage Endometrial Cancer: A Systematic Review of the Evidence, Guidelines, and Clinical Practice in the U.S.

“…A phase II nonrandomized prospective trial conducted by Obermair et al [16] Another phase II trial studied the efficacy of a "sandwich" regimen in 72 patients with stage I-IV USC (82% were stage I-II) who received postoperative treatment with 3 cycles of taxane and platinum-based chemotherapy, followed by EBRT to 45 Gy with or without VB, followed by an additional 3 cycles of chemotherapy [17]. Progression free survival (PFS) and OS for stage I-II were 65.5 6 3.6 and 76.5 6 4.3 months, respectively.…”